ESMO

Beyond's analysis on ESMO

• 2026-07-21 — Mabwell's ESMO 2026 oral presentation of clinical data for its Nectin-4-targeting ADC 9MW2821 highlights potential progress in triple-negative breast cancer therapy and could affect oncology investment sentiment

Recent news mentioning ESMO

• 2026-09-10 — Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference
• 2026-09-02 — El orden mundial estadounidense se está desmoronando
• 2026-08-31 — El consejero delegado de Vodafone declarará presencialmente para desmontar la “trama de falsedades” de los gestores de Finetwork
• 2026-08-04 — Por qué desmontar el éxito para triunfar mañana
• 2026-08-04 — Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses

Appears alongside

• MAP
• WCLC

Browse the full archive →